Mechanistically, glucose has been shown to induce SREBP1c expression of lipogenic genes specifically (56) A study in rats demonstrated that diet-induced MASLD causes an increase in SREBP1c expression, which may be involved in inhibiting IRS2 expression and causing resistance to insulin (57) ChREBP also regulates genes involved in lipogenesis such as liver pyruvate kinase, fatty acid synthase, acetyl co-A carboxylase and hyperactivation of these pathways leads to enhanced production of fatty acids and triglycerides (58) Both SREBP1c and ChREBP are activated in MASLD (59, 60). The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.